Latest Breaking News On - Clinic liver cancer - Page 2 : comparemela.com

Share this article Share this article SHANGHAI, June 6, 2021 /PRNewswire/ On June 4, 2021 (EST), OriginCell Therapeutics (Shanghai) Co., Ltd. ( OriginCell ), together with Lishui Central Hospital affiliated to Zhejiang University and Shanghai Changzheng Hospital, presented the updated data from the on-going trial of Ori-CAR-001, a GPC3 CAR-T cell therapy for the treatment of relapsed/refractory hepatocellular carcinoma (HCC), at the 2021 annual meeting of American Society of Clinical Oncology. Preliminary results from the study show promising safety and efficacy of Ori-CAR-001 in patients with GPC3-positive relapsed/refractory HCC. (PRNewsfoto/Yuanqi Biological Technology (Shanghai) Co., Ltd.) (PRNewsfoto/Yuanqi Biological Technology (Shanghai) Co., Ltd.)

United statesComunidad autonoma de catalunaJi jiansongEuropean association for the study of liverKey laboratory of imaging diagnosisAmerican society of clinical oncologyNational key rd programNational medical products administrationInvasive intervention research of zhejiang chinaCell therapySolid tumorsClinic liver cancerEuropean associationGood safety profileProfessor ji jiansongLishui central